Hinge Health Inc. (HNGE) - What Are Analysts Saying About This Stock?

Key Points

• Analysts are broadly bullish: Nineteen brokerages give Hinge Health a consensus “Moderate Buy” rating, with 15 buys, three holds and one strong buy. The average 12-month price target is $108, below the stock’s reported $115.02 price.
• Recent results showed strong growth: Hinge Health reported quarterly EPS of $0.59 versus the $0.28 consensus estimate, while revenue rose 53% year over year to $212.82 million.
• Insiders have been selling shares: Company insiders sold 1.02 million shares worth approximately $95.6 million over the past three months, although the transactions were made under pre-arranged Rule 10b5-1 plans.

Hinge Health Inc. (NYSE:HNGE - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nineteen brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $108.00.

HNGE has been the subject of several research reports. Stifel Nicolaus raised their target price on Hinge Health from $115.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday. Barclays lifted their price target on shares of Hinge Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, October 12th. Canaccord Genuity Group set a $105.00 price target on shares of Hinge Health in a report on Wednesday, August 5th. Wall Street Zen cut shares of Hinge Health from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Bank of America assumed coverage on shares of Hinge Health in a research note on Tuesday, September 29th. They issued a "buy" rating and a $110.00 price objective for the company.

Insider Buying and Selling at Hinge Health

In other Hinge Health news, CEO Daniel Perez sold 4,100 shares of the firm's stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $100.20, for a total transaction of $410,820.00. Following the completion of the transaction, the chief executive officer owned 4,100 shares in the company, valued at $410,820. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $94.14, for a total transaction of $3,106,620.00. Following the transaction, the president owned 666,909 shares of the company's stock, valued at approximately $62,782,813.26. This represents a 4.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,024,581 shares of company stock worth $95,632,761. Insiders own 18.92% of the company's stock.

Institutional Investors Weigh In On Hinge Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Argent Capital Management LLC bought a new position in shares of Hinge Health during the 3rd quarter worth approximately $3,376,000. Vista Investment Partners LLC acquired a new stake in Hinge Health in the 2nd quarter valued at $3,468,000. 11.2 Capital Management LLC acquired a new stake in Hinge Health in the 2nd quarter valued at $204,566,531. Assenagon Asset Management S.A. grew its position in Hinge Health by 2,141.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company's stock valued at $180,373,000 after acquiring an additional 1,772,182 shares during the period. Finally, Tidal Investments LLC bought a new stake in Hinge Health in the second quarter valued at $925,000.

Hinge Health Stock Up 1.0%

Hinge Health stock opened at $115.02 on Thursday. The business has a 50 day moving average price of $97.00 and a two-hundred day moving average price of $66.34. Hinge Health has a 12 month low of $30.08 and a 12 month high of $116.00. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of 89.86 and a beta of 1.37.

Hinge Health (NYSE:HNGE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.31. The company had revenue of $212.82 million for the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. Hinge Health's revenue for the quarter was up 53.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.59 EPS. On average, analysts expect that Hinge Health will post 1.25 earnings per share for the current fiscal year.

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.